Physician profile
Taylor Cater
NPI 1134689417
$1,156.33
in general payments reported to CMS, 2019-2025
20 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $319 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $260.24 | 2024-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $141.29 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $98.60 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $84.85 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $67.48 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $63.91 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $60.61 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $47.88 | 2024-2025 | |
| Mannkind Corporation | $45.21 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.95 | 2024-2025 | Jardiance |
| Amgen INC. | $40.79 | 2025 | Evenity, Prolia |
| Ibsa Pharma INC. | $34.20 | 2024-2025 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $25.68 | 2025 | Unithroid |
| Corcept Therapeutics | $25.07 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $21.82 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $21.42 | 2025 | Jatenzo |
| Ascensia Diabetes Care US INC. | $19.94 | 2025 | |
| Antares Pharma, INC. | $19.73 | 2025 | Xyosted |
| Cequr Corporation | $19.10 | 2025 | Cequr Simplicity |
| Rgh Enterprises LLC | $15.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Cater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.